Unlock instant, AI-driven research and patent intelligence for your innovation.

Oculospanin as a tumor specific antigen and methods and compositions utilizing same

a tumor specific and antigen technology, applied in the field of oculospanin as a tumor specific antigen and methods and compositions utilizing same, can solve the problems of limited range of monoclonal antibodies useful for tumor treatment, and the relationship between human oculospanin and tumors is still unknown, and achieve the effect of inhibiting oculospanin activity

Inactive Publication Date: 2007-02-01
SANKYO CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a method for inducing cytotoxicity in cancer cells by using antigen binding proteins that bind to oculospanin, a protein that is overexpressed in certain cancer cells, particularly melanoma. The invention also provides methods for screening for compounds that bind to oculospanin and for inducing cytotoxicity using these compounds. The invention further provides a composition of antigen binding proteins that bind to oculospanin and methods for using them for diagnostic and therapeutic purposes. The invention also provides a method for inducing cytotoxicity in cancer cells by using antigen binding proteins that bind to oculospanin.

Problems solved by technology

However, the range of monoclonal antibodies useful for tumor treatment is limited.
However, the relationship between human oculospanin and tumors is still unknown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oculospanin as a tumor specific antigen and methods and compositions utilizing same
  • Oculospanin as a tumor specific antigen and methods and compositions utilizing same
  • Oculospanin as a tumor specific antigen and methods and compositions utilizing same

Examples

Experimental program
Comparison scheme
Effect test

example 1

Screening of a Gene Specifically Expressed in a Cancer Cell

[0388] Expression profile analysis was performed, using an EST probe (Affymetrix GeneChip HG-133 probe 223795_at: manufactured by Affymetrix) having a nucleotide sequence partially overlapping with the sequence represented by Sequence ID No. 1 of the sequence listing, by use of the data base (GeneExpress Software System Release 1.4.2) provided by Genelogic company.

[0389] Expression of the human oculospanin gene in various cells was quantitatively compared by considering its transcription. As a result, the expression levels in 8 melanocyte samples were to found to be significantly high, compared to the levels in other cells samples, including 12 blood-cell samples, 6 glia cell samples, 62 epithelial cell samples (P values thereof were <0.0001, =0.0007, and <0.0001 sequentially in order, FIG. 1, upper panel).

[0390] Next, the expression levels of the human oculospanin gene were compared in samples derived from tissue. More s...

example 2

Acquisition of the Human Oculospanin Gene and Construction of Expression Plasmid

[0393] a) PCR Reaction

[0394] As a primer for amplifying human oculospanin cDNA by PCR, oligonucleotides having the following sequences were synthesized in accordance with a customary method.

5′-CACCATGGAGGAGGGGGAGAGGAGCC(Primer 1,C-3′Sequence ID No. 5of the sequencelisting)5′-GCCCCGGGCGGGTTTGGCAGCGG-3′(Primer 2,Sequence ID No. 6of the sequencelisting)

[0395] Note that Primer 1 is an oligonucleotide constructed by adding 4 bases, CACC, as a KOZAK sequence, upstream of the initiation codon of the human oculospanin gene, in other words, an oligonucleotide constructed by adding the 4 bases, the CACC sequence, to the 5′ side of the nucleotide sequence consisting of nucleotides No. 1 to 23 of the Sequence ID No. 1 of the sequence listing. The CACC sequence, since it forms a chain complementary to the 3′ terminus of the vector when it is integrated into the cloning vector pENTR / D-TOPO, makes it possible to in...

example 3

Introduction of the Human Oculospanin Gene into Cells, Confirmation that the Human Oculospanin Gene Product is Expressed, and Preparation of a Membrane Fraction from Human Oculospanin Expressing Cells for Use as an Immunogen

[0400] a) Transfection of NIH3T3 cells with the plasmid pcDNA3.1-DEST40-NM—031945

[0401] NIH3T3 cells were transfected with plasmid pcDNA3.1-DEST40-NM—031945 obtained in Example 2 as follows. The transfection of the NIH3T3 cells was performed by lipofection using the Lipofectamine 2000 Reagent manufactured by Invitrogen. To explain more specifically, first, NIH3T3 cells were grown in a 6 well plate up to a semi-confluent state. Next, the cells were washed once with antibiotic-free DMEM containing 10% fetal calf serum, then 200 μl of antibiotic-free DMEM containing 10% fetal calf serum was added to the cells. Then, to a 1.5 ml Eppendorf tube, 100 μl of serum-free medium (DMEM) and 2 μg of plasmid DNA (pcDNA3.1-DEST40-NM—031945) recovered in the aforementioned man...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and / or prevent cancer, and a pharmaceutical composition for treatment and / or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation-in-part application of U.S. application Ser. No. 11 / 223,812, filed Sep. 9, 2005, which is a continuation of International Application No. PCT / JP2004 / 003048, filed Mar. 9, 2004, which claims the benefit under 35 U.S.C. 365(c) of Japanese Application No. 2003-063648, filed Mar. 10, 2003; and of U.S. Application No. 10 / 548,688, filed with the U.S. Patent Office on Sep. 9, 2005, under 35 U.S.C. 371 from International Application No. PCT / JP2004 / 003048, filed Mar. 9, 2004, which claims the benefit under 35 U.S.C. 365(c) of Japanese Application No. 2003-063648. The entire disclosure of the above-listed prior applications is considered to be part of the disclosure of the instant application and is hereby incorporated by reference therein.FIELD OF THE INVENTION [0002] The present invention relates to compounds such as an antibodies useful in cancer treatment, a pharmaceutical composition for treating cancer cha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395G01N33/574C07K16/30C40B40/10C40B30/06G01N33/53A61K31/7088A61K48/00A61P17/00A61P35/00A61P43/00C07K16/32C07K16/42C12M1/00C12N15/09C12N15/12C12P21/08C12Q1/68G01N37/00
CPCC07K16/30C07K2317/732C12Q2600/158C12Q2600/136C12Q1/6886A61P17/00A61P35/00A61P43/00C07K16/32A61K39/395C07K16/42
Inventor ICHIKAWA, KIMIHISATAKAHASHI, SHUAGATSUMA, TOSHINORIFUKUCHI, KEISUKEHIRAI, TAKEHIRO
Owner SANKYO CO LTD